Novartis AG has synthesized new sodium channel protein type 5 subunit alpha (SCN5A; Nav1.5) blockers reported to be useful for the treatment of heart failure, long QT syndrome, hypertrophic cardiomyopathy, angina pectoris, myotonia, ventricular tachycardia, atrial and ventricular fibrillation, among others.
Myocardial fibrosis is a key process for heart failure development that may lead to severe phenotypes, including cardiac arrest or sudden death. Vasorin (VASN) is a protein with high expression in the cardiovascular system and its upregulation had been found to protect smooth muscle cells from calcification.
Implanted patches of iPS-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
Researchers from Fundación Jiménez Díaz and affiliated organizations have published data from a study that aimed to identify new genes involved in the progression of atherosclerosis, a chronic multifactorial inflammatory disease characterized by the accumulation of lipids and leukocytes within the arterial wall.
Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent hereditary angioedema attacks, marking the first global approval for the drug that was discovered and developed in Australia by CSL scientists.
A new bioprinting platform to create tissues that can change shape as a result of forces generated by the cells, similar to what happens naturally during organ development, was developed by researchers from the University of Galway, Ireland.
Innovo Therapeutics Inc. has patented new pyrazole derivatives acting as caspase-3 inhibitors and potentially useful for the treatment of pulmonary hypertension.
Nitric oxide exerts a fundamental protective role against cardiovascular disease onset by regulating blood pressure and vascular tone, inhibiting leukocyte adhesion and platelet aggregation, and preventing vascular endothelial cell proliferation.
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). The side effect of lean mass loss has dogged those taking GLP-1s. The study results didn’t support the company’s stock on the day of the data release as it had the previous four weeks.
Researchers from Children’s Hospital Los Angeles and the University of Southern California filed for protection of a pacemaker with a unique shape and configuration which is low profile.
RSS
